[Form 4] BioCardia, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) – Form 4 insider transaction

Director Andrew Scott Blank, through the Andy Blank Revocable Living Trust, participated in the company’s 30 June 2025 private placement. The trust purchased 72,289 common shares at $2.075 each and received 72,289 five-year warrants exercisable at $1.95 per share. The transaction was coded “P” (open-market/other purchase) and was executed concurrently with the institutional placement.

Following the purchase, Blank’s indirect holdings stand at 346,023 common shares and 314,522 warrants. No shares were disposed of other than a small 2,035-share adjustment noted as “D.” The filing signals continued insider confidence and modestly increases Blank’s economic exposure by roughly $150 thousand in cash invested (based on disclosed price).

• Transaction date: 30 Jun 2025; filing signed 2 Jul 2025.
• Insider role: Director; Form filed individually.
• All securities are held indirectly via the revocable living trust.

No earnings data or additional corporate developments were included in this filing.

Positive

• Director purchase: 72,289 common shares bought at $2.075, indicating insider confidence.
• Additional upside exposure: equal number of five-year warrants at $1.95 strike acquired.
• Increased ownership: holdings rise to 346,023 shares and 314,522 warrants, aligning director interests with shareholders.

Negative

• None.

Insights

Financial Analyst

TL;DR – Director adds ~72k shares & warrants in private placement; small but positive confidence signal.

The Form 4 shows Andrew Scott Blank increasing his indirect stake by 72,289 common shares and equal warrants, committing roughly $150k in fresh capital at a premium to the warrant strike. Although the size is not transformational relative to BioCardia’s float, insider participation alongside institutional buyers typically reflects belief in upcoming value catalysts such as clinical milestones or financing stability. With post-deal ownership of 346k shares and 314k warrants, Blank remains a meaningful aligned holder. The lack of disposals (aside from a minor 2,035-share adjustment) underscores a net accumulation stance. Overall impact is modestly positive for sentiment and governance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blank Andrew Scott

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		P		72,289(1)	A	$2.075(1)	346,023	I	See Footnote(2)
Common Stock								2,035	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$1.95	06/30/2025		P		72,289(1)		06/30/2025	06/30/2030	Common Stock	72,289(1)	(1)	314,522	I	See Footnote(2)

Explanation of Responses:

1. On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.

2. These shares are held by Andy Blank Revocable Living Trust, of which the Reporting Person serves as trustee.

	/s/ David McClung, by power of attorney	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BioCardia (BCDA) shares did the director buy?

The trust bought 72,289 common shares on 30 Jun 2025.

What price did the director pay for the new BCDA shares?

The purchase price was $2.075 per share.

Did the director receive warrants in the transaction?

Yes, 72,289 warrants exercisable at $1.95 and expiring 30 Jun 2030 were issued.

What is the director’s total BCDA share ownership after the transaction?

Indirect holdings now total 346,023 common shares.

How are the shares held?

All securities are held indirectly through the Andy Blank Revocable Living Trust.

Was any stock sold in this Form 4?

Only a small 2,035-share disposition is noted; the net position increased overall.